WO2017155350A1 - (±)-2-[2-(3-카르복시프로피오닐옥시)-3-디메틸아미노프로폭시]-3'-메톡시비벤질 또는 그의 염을 포함하는 경구용 약학 조성물 - Google Patents

(±)-2-[2-(3-카르복시프로피오닐옥시)-3-디메틸아미노프로폭시]-3'-메톡시비벤질 또는 그의 염을 포함하는 경구용 약학 조성물 Download PDF

Info

Publication number
WO2017155350A1
WO2017155350A1 PCT/KR2017/002614 KR2017002614W WO2017155350A1 WO 2017155350 A1 WO2017155350 A1 WO 2017155350A1 KR 2017002614 W KR2017002614 W KR 2017002614W WO 2017155350 A1 WO2017155350 A1 WO 2017155350A1
Authority
WO
WIPO (PCT)
Prior art keywords
release layer
pharmaceutical composition
sustained release
carboxypropionyloxy
dimethylaminopropoxy
Prior art date
Application number
PCT/KR2017/002614
Other languages
English (en)
French (fr)
Korean (ko)
Inventor
최연웅
하대철
권인호
김아영
송희용
정래훈
최보람
Original Assignee
한국유나이티드제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59789653&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2017155350(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 한국유나이티드제약 주식회사 filed Critical 한국유나이티드제약 주식회사
Priority to CN201780028153.9A priority Critical patent/CN109069435B/zh
Priority to JP2018547975A priority patent/JP7366542B2/ja
Publication of WO2017155350A1 publication Critical patent/WO2017155350A1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Definitions

  • the present invention relates to an oral pharmaceutical composition
  • an oral pharmaceutical composition comprising ( ⁇ ) -2- [2- (3-carboxypropionyloxy) -3-dimethylaminopropoxy] -3'-methoxybibenzyl or salts thereof as an active ingredient. More specifically, ( ⁇ ) -2- [2- (3-carboxypropionyloxy) -3-dimethylaminopropoxy] -3'-methoxybibenzyl or a salt-containing sustained release thereof that can be administered once a day It relates to an oral pharmaceutical composition.
  • antiplatelet drugs Drugs that prevent the formation of platelet clumps are called antiplatelet drugs. Most drugs have mechanisms that inhibit the process of blood clots and platelet activation. Aspirin, a typical drug, exhibits antiplatelet activity by blocking the action of cyclooxygenase and interfering with the action of thromboxane. Another typical drug, clopidogrel, inhibits ADP (adenosine diphosphate) receptor activation and inhibits platelet function.
  • ADP adenosine diphosphate
  • ( ⁇ ) -2- [2- (3-carboxypropionyloxy) -3-dimethylaminopropoxy] -3'-methoxybibenzyl hydrochloride is used to treat chronic arterial obstruction, chronic arterial obstruction. It is known to be useful as an active ingredient for improving ischemic symptoms of ulcers, pain and cold feeling, improving intermittent claudication, inhibitors of thrombosis and embolism in ischemic cerebrovascular disorders, and relieving pain following neuralgia after shingles (Korea Patent Publication 2006-0093677).
  • One aspect of the invention is ( ⁇ ) -2- [2- (3-carboxypropionyloxy) -3-dimethylaminopropoxy] -3'-methoxybibenzyl or a pharmaceutical thereof effective only once daily To provide an acceptable salt-containing pharmaceutical composition.
  • a pharmaceutical composition comprising a bilayer tablet consisting of a sustained release layer and an immediate release layer,
  • the sustained release layer and the immediate release layer each contain ( ⁇ ) -2- [2- (3-carboxypropionyloxy) -3-dimethylaminopropoxy] -3'-methoxybibenzyl or a salt thereof as an active ingredient. It provides a pharmaceutical composition.
  • the pharmaceutical composition according to one embodiment of the present invention is a pharmaceutical composition for improving or treating ischemic symptoms caused by chronic arterial occlusion, and may be administered once a day while maintaining an effective blood concentration of the drug for about 24 hours. Therefore, the pharmaceutical composition according to one embodiment of the present invention is not only preferable because it can significantly increase the medication compliance of the patient, it is possible to prevent the increase of the treatment period due to the omission of the patient, etc. It has the advantage that it can be used to improve or treat ischemic symptoms.
  • 5 to 6 are graphs showing the dissolution rate measurement results over time for the tablets prepared in Examples 11-15.
  • FIG. 7 shows time-blood concentration curves for three doses of the reference drug (Anflag® tablets) in humans.
  • FIG. 8 shows time-blood concentration curves of a single dose of bilayer tablets according to Example 15 in humans.
  • a pharmaceutical composition comprising a bilayer tablet consisting of a sustained release layer and an immediate release layer,
  • the sustained release layer and the immediate release layer each contain ( ⁇ ) -2- [2- (3-carboxypropionyloxy) -3-dimethylaminopropoxy] -3'-methoxybibenzyl or a salt thereof as an active ingredient. It provides a pharmaceutical composition.
  • the pharmaceutically acceptable salt of ( ⁇ ) -2- [2- (3-carboxypropionyloxy) -3-dimethylaminopropoxy] -3'-methoxybibenzyl may be an acid addition salt of an inorganic acid salt or an organic acid salt.
  • Examples include acetic acid, adipic acid, aspartic acid, 1,5-naphthalenedisulfonic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, 1,2-ethanedisulfonic acid, ethanesulfonic acid, ethylenediaminetetraacetic acid, fumaric acid, Glucoheptonic acid, Gluconic acid, Glutamic acid, Hydrogen iodide, Hydrobromic acid, Hydrochloric acid, Isetionic acid, Lactic acid, Maleic acid, Malic acid, Manderic acid, Methanesulfonic acid, Music acid, 2-naphthalenedisulfonic acid, Nitric acid, Oxalic acid, Parsity Salts with butyric acid, pentothenic acid, phosphoric acid, pivalic acid, propionic acid, salicylic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, or p-toluene
  • the pharmaceutically acceptable salt of ( ⁇ ) -2- [2- (3-carboxypropionyloxy) -3-dimethylaminopropoxy] -3'-methoxybibenzyl is ( ⁇ )- 2- [2- (3-carboxypropionyloxy) -3-dimethylaminopropoxy] -3'-methoxybibenzyl hydrochloride.
  • ( ⁇ ) -2- [2- (3-carboxypropionyloxy) -3-dimethylaminopropoxy] -3'-methoxybibenzyl hydrochloride may be prepared in Example 2 of Patent Document 1. It can manufacture based on description of.
  • ( ⁇ ) -2- [2- (3-carboxypropionyloxy) -3-dimethylaminopropoxy] -3'-methoxybibenzyl hydrochloride may be present in the form of any crystalline form, wherein the crystalline form is Form I , Form II, or any combination thereof.
  • Patent document 2 discloses a method for producing the crystalline form.
  • the pharmaceutical composition comprises about 30% of Form II of ( ⁇ ) -2- [2- (3-carboxypropionyloxy) -3-dimethylaminopropoxy] -3'-methoxybibenzyl hydrochloride More preferably about 70% or more.
  • the pharmaceutical composition comprises about 95% of Form II of ( ⁇ ) -2- [2- (3-carboxypropionyloxy) -3-dimethylaminopropoxy] -3'-methoxybibenzyl hydrochloride Or more, or 98% or more.
  • the active ingredient may be present in the immediate release layer and the sustained release layer in an arbitrary ratio, and in order to maintain the medicinal effect in a weight ratio of 1: 1 to 5, specifically about 1: 1 to 3, in the immediate release layer and the sustained release layer. It may be present, and more specifically may be present in a weight ratio of about 1: 2 to 2.5.
  • ( ⁇ ) -2- [2- (3-carboxypropionyloxy) -3-dimethylaminopropoxy] -3'-methoxybibenzyl hydrochloride is included in the immediate release layer and 100 mg in the sustained release layer Can be.
  • the pharmaceutical composition may be used to improve or treat chronic arterial occlusion, to improve or treat ischemic symptoms caused by chronic arterial occlusion, to improve intermittent claudication, to inhibit thrombosis and embolism in ischemic cerebrovascular disorders, or pain following neuralgia after shingles. It can be used as a reducing agent.
  • the ischemic symptoms include ulcers, pains, or colds (Patent Document 2).
  • the pharmaceutical composition may be administered by any route including oral administration, intramuscular, subcutaneous, or intravenous injection administration, nasal administration, or transdermal administration.
  • the pharmaceutical composition is a pharmaceutical composition for oral administration
  • the pharmaceutical composition may be administered in a dosage of about 200 to 400 mg / day active ingredient.
  • the dosage depends on these or other factors, depending on age, weight, general state of health, sex, meal, time of administration, method of administration, route of administration, rate of excretion, combination of drugs, and the extent of the condition of the patient being treated. It may vary, and it may increase or decrease according to expert judgment.
  • the pharmaceutical composition is a pharmaceutical composition for oral administration, the pharmaceutical composition may be administered as an active ingredient about 200 ⁇ 400 mg / day.
  • the pharmaceutical composition is a pharmaceutical composition for oral administration, wherein the pharmaceutical composition may be administered orally about 300 mg of an active ingredient once daily or on an empty stomach.
  • the dosage may also vary depending on age, weight, general health, sex, meal, time of administration, method of administration, route of administration, rate of excretion, combination of drugs, and the extent of the condition of the patient being treated. It may vary depending on factors and may increase or decrease according to expert judgment.
  • the pharmaceutical composition is an oral pharmaceutical composition comprising a sustained release monolayer, ie, a sustained release layer.
  • the pharmaceutical composition may include only a sustained release layer, or may be a pharmaceutical composition that is an oral multilayer tablet in the form of further comprising an immediate release layer together with the sustained release layer.
  • the pharmaceutical composition is a pharmaceutical composition which is an oral bilayer tablet comprising a sustained release layer and an immediate release layer.
  • sustained release layer refers to a layer in which the active ingredient is slowly dissolved and slowly eluted in the body after administration. Unlike the “fast release layer", the sustained release layer contains a substance that controls the dissolution of the active ingredient, that is, a sustained release agent, so that the active ingredient may be slowly eluted.
  • the sustained release agent may be used any sustained release agent known in the art.
  • the sustained release agent may be any sustained release agent known in the art.
  • the sustained-release agent is, for example, cellulose derivatives such as hydroxypropylmethyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, or sodium carboxymethyl cellulose, polyethylene oxide, polyvinylpyrrolidone (Polyvinylpyrrolidone ), Guar gum, locust bean gum, polyvinylacetate, polyvinylacetate phthalate, polymethacrylate (Eudragit), polyacrylic acid, carbomer (e.g. carbomer 941), glycerol monostearate and poloxamer, and any combination thereof
  • the sustained release agent may be 10 to 30% by weight, preferably 15 to 25% by weight relative to the weight of the sustained release layer. have.
  • the sustained release agent comprises a combination of hydroxyl propyl methyl cellulose and carbomer.
  • the hydroxypropyl methyl cellulose may be hydroxypropyl methyl cellulose having any viscosity used as a sustained release agent in the art, in one embodiment 2,000 cps to 200,000 cps, preferably 4,000 cps to 100,000 cps Can be. If it is less than 2,000cps, a large amount of hydroxypropylmethylcellulose is required, and the size of the tablet becomes large, and if the viscosity exceeds 200,000cps, it may be difficult to uniformly mix with the drug. In one embodiment, the viscosity of hydroxypropylmethylcellulose may be 80,000 cps to 120,000 cps.
  • Sustained-release tablets containing pharmacologically active ingredients show swelling of the tablet during elution.
  • the matrix of the release controlling polymer is not strong, the matrix may be partially damaged (erosion) and the tablet may disintegrate, which may lead to rapid drug release.
  • a mixture of hydroxypropylmethylcellulose and carbomer can be used as a release controlling polymer.
  • carbomer When carbomer is used as a drug release controlling polymer together with hydroxypropylmethylcellulose, it has the effect of strengthening the matrix in the sustained-release tablet and maintaining the form when the tablet is expanded and maintaining the matrix of the tablet to prevent erosion of the tablet. Maintain a constant dissolution rate.
  • the combination of the sustained release agent may be 15 to 25% by weight hydroxypropylmethylcellulose relative to the total weight of the sustained release layer, 1 to 25% by weight carbomer, more specifically, 1 to 10% by weight
  • the hydroxypropyl methyl cellulose: carbomer may be a weight ratio of 2: 1 to 20: 1, specifically 4: 1 to 18: 1, and more specifically 8: 1 to 15: 1. have.
  • the dissolution rate of the pharmacologically active ingredient may be lowered under alkaline conditions.
  • the carbomer is an anionic polymer, and when gelled in an alkaline environment, the carbomer is combined with an active ingredient having a cation. This is because drug release may be suppressed in an alkaline environment.
  • the weight ratio of the hydroxypropyl methyl cellulose and the carbomer is more than 20: 1, it is difficult to uniformly mix between the release control polymer, the stability may be deteriorated, and the sustained release effect is so large that sufficient elution is not achieved and effective blood There is a fear that the concentration cannot be reached.
  • the weight ratio is less than 2: 1, it is difficult to form a matrix in tablets, and thus, sufficient sustained release effect of the drug does not appear, and thus, once daily administration may not be possible or side effects may occur.
  • the combination of the sustained-release agent can keep the blood concentration almost constant by suppressing the rapid release of the active ingredient (see Experimental Example 2). Therefore, there is an advantage that the fear of possible side effects due to the rapid release of the active ingredient can be solved.
  • the continuous release of the active ingredient can be made, so that the effective blood concentration can be maintained throughout the day by oral administration only once a day, it is also preferable in terms of the number of administration. Therefore, there is no abrupt release of the drug, so there is no fear of side effects, and since it is possible to administer once a day by continuous release, medication compliance can be increased.
  • the sustained release layer of the pharmaceutical composition may further include a pharmaceutical additive selected from the group consisting of excipients, binders, disintegrants, glidants, and any combination thereof.
  • the sustained release layer contains a disintegrant.
  • the sustained release layer generally does not contain a disintegrant for the sustained release of the active ingredient, but the pharmaceutical composition according to the embodiment of the present invention has a sustained release layer containing a disintegrant so that the effective ingredient dissolution of the active ingredient in the latter part after oral administration of the pharmaceutical composition is 100 Even closer to% (see Experimental Example 2). Therefore, the pharmaceutical composition according to the embodiment has an advantage that the dissolution of the active ingredient is almost completely compared to the case that does not contain a disintegrant, which can have a significantly improved bioavailability.
  • the meaning that the dissolution can be “close to 100%” herein means at least 90% or more, specifically 93% or more, more specifically 95% or more, even more specifically 97% or more, and more specifically It can mean more than 98%.
  • the disintegrant can be any disintegrant used in the manufacture of tablets.
  • the disintegrant may be selected from, for example, sodium starch glycolate, crospovidone, croscarmellose sodium, and any combination thereof, but is not limited thereto.
  • the disintegrant is sodium starch glycolate.
  • the content of the disintegrant may be in the range of about 1 to 5% by weight based on the total weight of the sustained-release layer, if too large outside the above range, the disintegration effect is increased, which may inhibit the slow release of the active ingredient, too little In this case, there is a fear that there is no sufficient disintegration effect, so that the emission may not be nearly 100%.
  • the sustained-release layer may be prepared according to any method for preparing a sustained-release layer known in the art, for example, by granulating together the active ingredient, the sustained-release agent, and the pharmaceutical additive, and then using a tableting machine in tablet form. It can be prepared by tableting.
  • the granules comprise dry granules or wet granules. In one embodiment, the granules are wet granules, which is preferred in terms of tabletting when wet granulating. Dry granules may cause problems such as tablet breakage during tableting.
  • immediate release layer refers to a layer which dissolves rapidly in the body after administration and rapidly elutes the active ingredient contained in the immediate release layer. While the term “sustained release layer” requires a substance to control the release of the active ingredient, the immediate release layer does not contain a substance that controls the release of the drug. Therefore, the immediate release layer can quickly elute the active ingredient, and the immediate release layer may optionally include a fast-acting excipient.
  • the pharmaceutical composition comprises an immediate release layer comprising a fast-acting excipient.
  • fast-acting excipient means any excipient that serves to aid the rapid release of the active ingredient in the immediate release layer.
  • the fast-acting excipient may use a fast-acting excipient known in the art, and may use an excipient of the same kind as lactose, sugar alcohol, microcrystalline cellulose, water-soluble polymer, or an oil-based base.
  • the fast-acting excipient is lactose or microcrystalline cellulose.
  • the immediate release layer enables the rapid release of the active ingredient, thereby allowing the effective blood concentration of the active ingredient to be reached quickly upon oral administration. Therefore, the pharmaceutical composition may ensure a faster drug due to the presence of the immediate release layer.
  • the immediate release layer may further include a pharmaceutical additive selected from the group consisting of a binder, a stabilizer, a disintegrant, a lubricant, a pH adjuster, a stabilizer, and any combination thereof.
  • a pharmaceutical additive selected from the group consisting of a binder, a stabilizer, a disintegrant, a lubricant, a pH adjuster, a stabilizer, and any combination thereof.
  • the immediate release layer may be stabilizer, For example citric acid.
  • the stabilizer may be about 0.4% to 2.8% by weight, specifically 0.8% to 2.2% by weight, based on the total weight of the immediate release layer.
  • the weight ratio of the stabilizer is less than 0.4% by weight, the stabilizing effect in acid may be reduced. If the 2.8% by weight is exceeded, the initial dissolution rate may drop. This is because when the stabilizer is used in excess, the pH of the active ingredient may be lower than that of the fast pH condition (pH 4.0).
  • the immediate release layer may be prepared according to any method for preparing a rapid release layer known in the art, and for example, the active ingredient, the rapid release excipient, and the pharmaceutical additive are granulated together and then tableted using a tableting machine. It can be prepared by tableting.
  • the granules comprise dry granules or wet granules. In one embodiment, the granules are wet granules, which is preferred in terms of tabletting when wet granulating. Dry granules may cause problems such as tablet breakage during tableting.
  • the excipient may be any excipient known in the art, for example microcrystalline cellulose, lactose, low substituted hydroxypropyl cellulose, calcium phosphate, hard silicic anhydride, pregelatinized starch, corn starch, potato starch, white sugar , Mannitol, dextrin, precipitated calcium carbonate and any combination thereof, but is not limited thereto;
  • the binder may be any binder known in the art and may be selected from, for example, hydroxypropylcellulose, polyvinylpyrrolidone, povidone, copovidone, macrogol, and any combination thereof. But may not be limited to this;
  • the disintegrant can be any disintegrant known in the art, for example sodium starch glycolate, polyvinylpyrrolidone, crospovidone, croscarmellose sodium, pregelatinized starch (Starch 1500 or Premojel), low-substituted hydroxypropyl cellulose, starch, alginic acid, sodium alginate, and combinations thereof, but is not limited thereto;
  • the glidants can be any glidants known in the art, for example, metal stearates such as stearic acid, calcium stearate or magnesium stearate, talc, colloidal silica, sucrose fatty acid esters, hydrogenated vegetable Oil, high melting point waxes, glyceryl fatty acid esters, glycerol dibehenate, and any mixtures thereof, and any combination thereof, but may be selected from the group consisting of, but not limited to.
  • metal stearates such as stearic acid, calcium stearate or magnesium stearate, talc, colloidal silica, sucrose fatty acid esters, hydrogenated vegetable Oil, high melting point waxes, glyceryl fatty acid esters, glycerol dibehenate, and any mixtures thereof, and any combination thereof, but may be selected from the group consisting of, but not limited to.
  • the sustained release layer and immediate release layer of the oral multilayer tablet or oral bilayer tablet pharmaceutical composition may contain the active ingredient, respectively, to provide release of both sustained release and immediate release of the active ingredient.
  • the active ingredient As it provides release of both sustained and immediate release, it is possible to reach the effective blood concentration quickly by the effective release of active ingredient, so that it can be shown fast effect and can be administered by the release of continuous active ingredient provided by the sustained release layer. Frequency can be significantly reduced, for example, once daily. Therefore, the pharmaceutical composition according to the present invention may be provided as a once-a-day administrable preparation capable of rapid medicinal effect and continuous action.
  • the oral multilayer tablet or oral bilayer tablet is a granule prepared for the preparation of the immediate release layer as a first tableting tablet with a tableting machine as a first layer, the sustained-layer granules mixed with a lubricant and a post-mixing agent on the first layer
  • Secondary tablets may be prepared by filling and secondary tableting, and the order of the immediate release layer and the sustained release layer may be changed.
  • a film coating process may be further performed with the coating agent.
  • the preparation of the immediate release layer granules, the preparation of the sustained release layer granules, the first tableting and the second tableting, and the specific conditions of the film coating may be appropriately performed using techniques known in the art.
  • the pharmaceutical composition is a bilayer or multilayer tablet comprising an immediate release layer and a sustained release layer, and due to the inclusion of such immediate release layer and the sustained release layer, both rapid release and sustained release can be obtained.
  • the pharmaceutical composition which is a two-layer or multilayer tablet comprising an immediate release layer and a sustained release layer, is prepared under the dissolution test conditions according to the second method of the Korean Pharmacopoeia (paddle method) (eluate: 900 mL of water, stirring rate: 50 rpm, test solution temperature: 37 ⁇ 0.5), elution rate of 25 to 45% in 60 minutes, 45 to 70% in 5 hours and 80% or more in 24 hours (see Experimental Example 2).
  • the pharmaceutical composition can be administered orally once a day by such an dissolution aspect.
  • the maximum blood concentration (C max ) value of the blood donor after oral administration may be 467.3 to 721.4 ⁇ g / L.
  • the geometric mean ratio (postprandial / fasting) of postprandial administration to fasting administration of the highest blood concentration (C max ) value of the blood donor after oral administration may be 0.57 to 0.73.
  • the time (T max ) to reach the highest blood concentration of the recipient after oral administration may be 0.5 to 3.97 hours.
  • the half-life ( t 1/2 ) of the drug after oral administration may be 1.45 to 3.23 hours. According to the pharmacokinetic parameters, it was confirmed that the absorption of the drug during the postprandial administration and the peak blood concentration are also lower than the fasting administration. Therefore, the pharmaceutical composition may vary in the amount of the active ingredient contained depending on the dosage regimen.
  • the pharmaceutical composition comprises (dimethylamino) -3- [2- [2- (3-methoxyphenyl) ethyl] phenoxy] -2-propanol hydrochloride (BP-984), which is a representative flexible substance of the active ingredient. It was found to contain less than 0.5% by weight according to the general test liquid chromatography method (see Experimental Example 3). Therefore, it was confirmed that the pharmaceutical composition can be prepared as a stable formulation that allows the continuous release of the active ingredient, while forming a flexible substance below the baseline.
  • Example 1-10 ( ⁇ ) -2- [2- (3- Carboxypropionyloxy ) -3- Dimethylaminopropoxy ] -3'-methoxybibenzyl Hydrochloride Preparation of Sustained Release Tablets
  • a binding solution in which povidone was dissolved in anhydrous ethanol was separately prepared, and ( ⁇ ) -2- [2- (3-carboxypropionyloxy) -3-dimethylaminoprop Foxy] -3'-methoxybibenzyl hydrochloride, lactose hydrate, hypromellose carbomer 941, and sodium starch glycolate, followed by association, granulation, and drying with the binding solution. It was sieved through a sieve and sieved to prepare a sustained-release layer granules. Then, the prepared sustained layer granules were postmixed with magnesium stearate. The granules were compressed to a hardness of about 14 kgf to prepare a sustained release tablet. Then, Opadry white film coating of Table 2 below.
  • Tester Method 2 of the Pharmacopoeia General Test Method (paddle method)
  • Test solution temperature 37 ⁇ 0.5 °C
  • Example 1-10 Six tablets of each sustained-release tablet prepared in Example 1-10 were eluted and tested by dissolution test method 2 (paddle method) of the Korean Pharmacopoeia General Test Method according to the above conditions. filter) and the first filtrate 5 mL was discarded and the next filtrate was used as the sample solution.
  • the active ingredient ( ⁇ ) -2- [2- (3-carboxypropionyloxy) -3-dimethylaminopropoxy] -3'-methoxybibenzyl hydrochloride standard was dried at 105 DEG C for 2 hours and about 33.3 mg Weigh accurately and add 80 mL of water to dissolve it, and add water to make exactly 100 mL (as measured immediately after preparation).
  • the peak areas A T and A S of the active ingredient were measured by the liquid chromatograph method of the Korean Pharmacopoeia General Test Method with 40 ⁇ L of the test solution and the standard solution after 60 minutes, 5 hours, and 24 hours after the start of dissolution.
  • the dissolution rate was calculated by the following formula.
  • Oil amount Adjust to keep the active ingredient about 7 minutes.
  • Examples 3 and 4 showed a sustained release pattern in which the drug was released at a constant rate for 24 hours, but the dissolution rate decreased in the latter part of the drug at a final dissolution rate of about 92%.
  • the final dissolution rate of the latter part was improved to about 95%.
  • the dissolution rate of 24 hours was about 97%, which showed a further improvement in the latter dissolution rate of the active ingredient.
  • Example 11-15 ( ⁇ ) -2- [2- (3- Carboxypropionyloxy ) -3- Dimethylaminopropoxy ] -3'-methoxybibenzyl Hydrochloride Preparation of Containing Two-Layered Tablets
  • immediate release layer granules containing ( ⁇ ) -2- [2- (3-carboxypropionyloxy) -3-dimethylaminopropoxy] -3'-methoxybibenzyl hydrochloride were prepared.
  • a binding solution in which povidone was dissolved in anhydrous ethanol was separately prepared, and ( ⁇ ) -2- [2- (3-carboxypropionyloxy) -3-dimethylaminoprop Foxy] -3'-methoxybibenzyl hydrochloride, lactose hydrate, microcrystalline cellulose 101, hypromellose, carbomer 941, and sodium starch glycolate, followed by association, granulation, and drying After the process, the mixture was sieved through a No. 20 sieve to prepare a sustained-release layer granules. Then, the prepared sustained layer granules were postmixed with magnesium stearate.
  • Secondary tablets were prepared by first tableting the immediate release layer granules at a hardness of about 3 kgf, and then filling the post-mixed sustained release layer granules thereon with secondary tableting at a hardness of about 15 kgf. Then, the film was coated with the coating material of Table 3 to complete the two-layered tablet.
  • Example 15 75 mg of the bilayer tablet containing the active ingredient of Example 15 was precisely weighed, dissolved in 0.01 mol / L hydrochloric acid, and the solution was diluted to 100 mL with 0.01 mol / L hydrochloric acid as a sample solution.
  • BP-984 standard is dried at 105 ° C for 2 hours, precisely weighed 37.5 mg is dissolved in 0.01 mol / L hydrochloric acid, and accurately prepared to be 100 mL with 0.01 mol / L hydrochloric acid. Take exactly 1 mL of the standard stock solution and make exactly 100 mL with 0.01 mol / L hydrochloric acid.
  • Oil amount Adjust so that the holding time of the active ingredient ( ⁇ ) -2- [2- (3-carboxypropionyloxy) -3-dimethylaminopropoxy] -3'-methoxybibenzyl hydrochloride is about 7 minutes. .
  • Reproducibility of the system Relative standard deviation of the peak area of the active ingredient is not more than 2.0% when the test is repeated 6 times with 20 ⁇ L of standard solution under the above conditions.
  • BP-984 was found to be 0.5% or less.
  • Example 15 This trial was to pharmacokinetic properties in healthy volunteers in a single dose and two layers defined in Example 15 confirmed (pharmacokinetic properties) and comparing it to a plaque ® not defined when orally available in bangjeong. In addition, the effect of food was examined by comparing the pharmacokinetic characteristics of the double-layered tablets of Example 15 after the meal and fasting.
  • Each subject was randomized to either Group A (RT-TF) or Group B (T-TF-R) or Group C (TF-RT) or Group D (TF-TR), Group E (TR-TF) or Group F.
  • R control drug (fasting)
  • T test drug (fasting)
  • TF test drug (postprandial)
  • Subjects in group A took the control drug on an empty stomach in the first phase, the test drug on the fasting phase in the second phase, and the test drug in the post-prandial phase in the third phase. The drug was administered at the time of dosing, and then the drug was administered to the next time.
  • Test drug before each administration (0h), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24h (15 times in total)
  • the collected blood was separated from the plasma at about 4 ° C. and 3,000 rpm in a centrifuge for 10 minutes, and then divided into three labeled eppendorf tubes by 1.5 mL and stored at -70 ° C. for freezing.
  • Figure 8 shows the time-blood concentration curve of a single dose of a bilayer tablet according to Example 15 of the present invention in humans.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/KR2017/002614 2016-03-11 2017-03-10 (±)-2-[2-(3-카르복시프로피오닐옥시)-3-디메틸아미노프로폭시]-3'-메톡시비벤질 또는 그의 염을 포함하는 경구용 약학 조성물 WO2017155350A1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201780028153.9A CN109069435B (zh) 2016-03-11 2017-03-10 包含沙格雷酯或其盐的口服药物组合物
JP2018547975A JP7366542B2 (ja) 2016-03-11 2017-03-10 （±）－２－［２－（３－カルボキシプロピオニルオキシ）－３－ジメチルアミノプロポキシ］－３’－メトキシビベンジルまたはその塩を含む経口用薬学組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0029881 2016-03-11
KR1020160029881A KR101790286B1 (ko) 2016-03-11 2016-03-11 (±)-2-[2-(3-카르복시프로피오닐옥시)-3-디메틸아미노프로폭시]-3'-메톡시비벤질 또는 그의 염을 포함하는 경구용 약학 조성물

Publications (1)

Publication Number Publication Date
WO2017155350A1 true WO2017155350A1 (ko) 2017-09-14

Family

ID=59789653

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/002614 WO2017155350A1 (ko) 2016-03-11 2017-03-10 (±)-2-[2-(3-카르복시프로피오닐옥시)-3-디메틸아미노프로폭시]-3'-메톡시비벤질 또는 그의 염을 포함하는 경구용 약학 조성물

Country Status (4)

Country Link
JP (1) JP7366542B2 (ja)
KR (1) KR101790286B1 (ja)
CN (1) CN109069435B (ja)
WO (1) WO2017155350A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102261748B1 (ko) 2019-02-13 2021-06-08 한국바이오켐제약 주식회사 사포그릴레이트염산염의 제조방법 및 이를 포함하는 약학제제
US20230040902A1 (en) * 2019-12-19 2023-02-09 Celltrion Inc. Pharmaceutical Formulation Comprising Cibenzoline or Salt Thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101265491B1 (ko) * 2010-08-30 2013-05-16 주식회사 유유제약 사포그릴레이트염산염을 함유하는 용출률이 조절된 경구용 다층정제 및 이의 제조방법
KR101320802B1 (ko) * 2010-02-16 2013-10-23 주식회사 드림파마 방출 제어형 사포그릴레이트 염산염 함유 다층 정제
CN102552165B (zh) * 2012-01-05 2014-07-16 金陵药业股份有限公司 一种盐酸沙格雷酯缓释微丸及其制备方法
KR101534606B1 (ko) * 2011-11-08 2015-07-10 알보젠코리아 주식회사 사포그릴레이트의 안정화된 지속 방출 제제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120060983A (ko) * 2010-10-04 2012-06-12 근화제약주식회사 염산사포그릴레이트를 포함하는 서방화 제제 및 이의 제조방법
CN103284970A (zh) * 2012-02-29 2013-09-11 锦华制药株式会社 盐酸沙格雷酯缓释制剂及制备方法
KR20130135493A (ko) * 2012-06-01 2013-12-11 씨제이제일제당 (주) 안정화된 사포그릴레이트 염산염을 포함하는 경구용 서방성 매트릭스 제제 및 그의 제조방법
CA2877774C (en) 2012-07-12 2017-07-18 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101320802B1 (ko) * 2010-02-16 2013-10-23 주식회사 드림파마 방출 제어형 사포그릴레이트 염산염 함유 다층 정제
KR101265491B1 (ko) * 2010-08-30 2013-05-16 주식회사 유유제약 사포그릴레이트염산염을 함유하는 용출률이 조절된 경구용 다층정제 및 이의 제조방법
KR101534606B1 (ko) * 2011-11-08 2015-07-10 알보젠코리아 주식회사 사포그릴레이트의 안정화된 지속 방출 제제
CN102552165B (zh) * 2012-01-05 2014-07-16 金陵药业股份有限公司 一种盐酸沙格雷酯缓释微丸及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM, T. -E. ET AL.: "Pharmacokinetics of a New Once-daily Controlled-release Sarpogrelate Hydrochloride Compared with Immediate-release Formulation and the Effect of Food", JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, vol. 39, 2014, pages 192 - 195, XP055421651 *
TATAVARTI, A. S. ET AL.: "Influence of Methacrylic and Acrylic Acid Polymers on the Release Performance of Weakly Basic Drugs from Sustained Release Hydrophilic Matrices", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 93, no. 9, 2004, pages 2319 - 2331, XP002676237 *

Also Published As

Publication number Publication date
KR20170106126A (ko) 2017-09-20
JP7366542B2 (ja) 2023-10-23
KR101790286B1 (ko) 2017-10-26
JP2019507795A (ja) 2019-03-22
CN109069435A (zh) 2018-12-21
KR101790286B9 (ko) 2022-01-28
CN109069435B (zh) 2022-06-28

Similar Documents

Publication Publication Date Title
WO2018070671A1 (ko) 레날리도마이드의 경구용 정제 조성물
WO2020040438A1 (ko) 에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제
WO2019117502A1 (ko) 모사프리드와 라베프라졸을 함유하는 유핵정 복합제제
WO2011152652A2 (ko) 1일 1회 투여로 최적의 약리학적 임상 효과를 제공하는 아세클로페낙 서방성 제제
WO2020242132A1 (ko) 디메틸푸마르산염을 함유한 장용성 정제
WO2016159535A1 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
WO2018097629A1 (ko) 바레니클린 서방성 제제 및 이의 제조 방법
WO2017155350A1 (ko) (±)-2-[2-(3-카르복시프로피오닐옥시)-3-디메틸아미노프로폭시]-3'-메톡시비벤질 또는 그의 염을 포함하는 경구용 약학 조성물
WO2017146286A1 (ko) 친수성서방폴리머의 매트릭스를 이용한 은행잎 추출물의 약학조성물 및 이를 이용한 경구용 서방성 제제
WO2018062685A1 (ko) 칸데사르탄 및 암로디핀을 포함하는 단일층으로 이루어진 복합제
WO2018062964A1 (ko) 용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법
WO2013157840A1 (ko) 안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물
WO2021125824A1 (ko) 시벤졸린 또는 이의 염을 포함하는 약학 제형
WO2012077968A2 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
WO2015012633A1 (ko) 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
WO2020022824A1 (ko) 에독사반을 포함하는 약학적 제제 및 이의 제조방법
WO2015147467A1 (en) Pharmaceutical preparation comprising telmisartan and (s)-amlodipine with improved oxidative stability
WO2021167364A1 (en) Pharmaceutical composition comprising esomeprazole and sodium bicarbonate having excellent release properties
WO2021020771A1 (ko) 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
WO2019199132A1 (ko) 다양한 용량의 레날리도마이드의 경구용 정제 조성물
WO2019245150A1 (ko) 실로스타졸과 스타틴계약물을 함유하는 약학 조성물
WO2013169082A1 (ko) 보센탄 제어방출성 경구제제
WO2013187700A1 (ko) 메트포르민 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 복합제제
WO2019212214A1 (ko) 약학적 제제
WO2021137504A1 (ko) 안정성이 향상된 약제학적 제제 및 그 제조 방법

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2018547975

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17763610

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17763610

Country of ref document: EP

Kind code of ref document: A1